.

0 (hodnocen0 x )

EB

ONLINE

Singapore : World Scientific Publishing Company, 2020

1 online resource (372 pages)

ISBN 9789811232701 (electronic bk.)

ISBN 9789811232695

Print version: Altman, Russ B Biocomputing 2021 - Proceedings Of The Pacific Symposium Singapore : World Scientific Publishing Company,c2020 ISBN 9789811232695

Intro -- Contents -- Preface -- ACHIEVING TRUSTWORTHY BIOMEDICAL DATA -- Session Introduction: Achieving Trustworthy Biomedical Data Solutions -- 1. Introduction -- 2. Preserving Privacy and Explaining Decisions of Artificial Intelligence -- 3. Sharing Genomic and Health Records -- 4. Deploying Digital Health Solutions -- 5. Crowdsourcing Healthcare -- 6. Considering the Bioethics -- 7. Anticipating the Future -- References -- Selection of Trustworthy Crowd Workers for Telemedical Diagnosis of Pediatric Autism Spectrum Disorder -- 1. Introduction -- 2. Methods -- 2.1. Clinically representative videos -- 2.2. Crowdsourcing task for Microworkers -- 2.3. Classifier to evaluate performance -- 2.4. Metrics evaluated -- 2.5. Prediction of crowd worker performance from metrics -- 3. Results -- 3.1. Correlation between metrics and probability of the correct class -- 3.2. Regression prediction of the mean probability of the correct class -- 4. Discussion and Future Work -- 5. Conclusion -- 6. Acknowledgments -- References -- Differential Privacy Protection Against Membership Inference Attack on Machine Learning for Genomic Data -- 1. Introduction -- 2. Related Work -- 3. Methods -- 3.1. Membership inference attack (MIA) -- 3.2. Di erential privacy (DP) -- 4. Experimental Setup -- 4.1. Dataset -- 4.2. Implementation of target models -- 4.3. Implementation of DP -- 4.4. Implementation of MIA -- 4.5. Evaluation metrics -- 5. Results -- 5.1. Vulnerability of target model against MIA without DP protection -- 5.2. Impact of privacy budget on the target model accuracy -- 5.3. E ectiveness of DP against MIA -- 5.4. E ect of model sparsity -- 6. Conclusion -- References -- Making Compassionate Use More Useful: Using Real-World Data, Real-World Evidence and Digital Twins to Supplement or Supplant Randomized Controlled Trials -- 1. Introduction.

1.1 Compassionate use -- 1.2 Compassionate use during the pandemic -- 1.3 What is an RCT? -- 1.3 EA data and NDAs -- 2. Real-World Information -- 2.1 Real-world data in trials -- 2.2 Real-world data and real-world evidence -- 2.2 Real-world limitations -- 3.0 Making RWD Work -- 3.1 Digital twins -- 4.0 Conclusions -- References -- ADVANCED METHODS FOR BIG DATA ANALYTICS IN WOMEN’S HEALTH -- Session Introduction: Advanced Methods for Big Data Analytics in Women’s Health -- 1. Introduction -- 2. Session Summary -- 2.1. Full-length papers -- 3. Discussion -- References -- Intimate Partner Violence and Injury Prediction from Radiology Reports -- 1. Introduction -- 2. Related Work -- 2.1. Intimate partner violence -- 2.2. Clinical prediction -- 2.3. Natural language processing -- 3. Dataset -- 3.1. IPV patient selection -- 3.2. Control group selection -- 3.3. Injury labels -- 3.4. Data cleaning -- 3.5. Demographic data -- 4. Methodology -- 4.1. Experiment setup -- 4.2. Models -- 4.3. Evaluation -- 4.3.1. Prediction and predictive features -- 4.3.2. Error analysis -- 4.3.3. Report-program date gap -- 5. Results -- 5.1. IPV and injury prediction and predictive features -- 5.2. Error analysis -- 5.3. Report-program date gap -- 6. Discussion and conclusion -- References -- Not All C-sections Are the Same: Investigating Emergency vs. Elective C-section deliveries as an Adverse Pregnancy Outcome -- 1. Background and Significance -- 2. Methods -- 2.1. Dataset characteristics -- 2.2. Identification of delivery outcomes -- 2.2.1. Cesarean section deliveries -- 2.2.2. Preterm birth, stillbirth, and multiple birth deliveries -- 2.3. Integration of data from encounter records -- 2.4. Generalized regression models -- 3. Results -- 3.1. Utilization of cesarean section codes -- 3.2. Admission types recorded in encounter records.

2.6. Semantic novelty -- 2.6.1. Strategy T1: Novel paper detection based on semantic distance -- 2.6.2. Strategy T2: Detection of novel papers that may constitute a trend -- 2.6.3. Strategy Y1: Detection of a group of novel papers based on their mean vector -- 2.6.4. Strategy Y2: Proportion of novel papers -- 3. Results and Discussion -- 4. Conclusions -- 5. Supplementary Information -- 6. Acknowledgements -- References -- TreeFix-TP: Phylogenetic Error-Correction for Infectious Disease Transmission Network Inference -- 1. Background -- 2. Methods -- 2.1. Minimizing inter-host transmissions -- 2.2. Description of TreeFix-TP -- 2.3. Evaluation using simulated data sets -- 2.3.1. Data set generation -- 2.3.2. Evaluating reconstruction accuracy -- 3. Results -- 3.1. Phylogenetic error correction results -- 3.2. Source recovery in HCV outbreaks -- 3.3. Running time and scalability -- 4. Discussion and Conclusions -- Acknowledgments -- Authors’ Contributions -- Supplementary Material -- References -- SARS-CoV-2 Drug Discovery based on Intrinsically Disordered Regions -- 1. Introduction -- 2. Methods -- 2.1. Molecular docking -- 2.1.1. Data collection -- 2.1.2. Data preprocessing -- 2.1.3. Target file generation -- 2.1.4. Flexible docking -- 2.1.5. Ensemble docking -- 2.2. Statistical model -- 2.2.1. Chemprop -- 2.2.2. Data and training -- 3. Results -- 3.1. Interaction modelling -- 3.2. Activity prediction -- 4. Conclusion -- 5. Acknowledgements -- References -- Feasibility of the Vaccine Development for SARS-CoV-2 and Other Viruses Using the Shell Disorder Analysis -- 1. Introduction -- 1.1. SARS-COV-2 Vaccine -- 1.2. Shell disorder analysis of HIV and other viruses -- 1.3. Spinoff projects including coronaviruses: Shell disorder and modes of transmission -- 1.4. Yet another spinoff: Correlations between the inner shell disorder and virulence.

9. Acknowledgements.

2. Results -- 2.1. Clustering of CoV based mainly on NPID -- 2.2 Outer shell disorder is an indicator for the presence or absence of effective vaccines -- 2.3. A disordered outer shell provides an immune evasion tactic: Viral shapeshifting -- 2.4. SARS-CoV-2: Exceptionally hard shell (low MPID) associated with burrowing animals and buried feces -- 2.5. Behavior of the animal hosts matters in the evolutions of the viruses: EIAV vs. HIV -- 2.6. Feasibility of developing attenuated vaccine strains for SARS-CoV-2 -- 3. Discussion -- 3.1. Links between respiratory transmission, N (Inner shell) disorder, and virulence: Viral load in body fluids vs. vital organs -- 3.2. Greater disorder in the inner shell proteins provide means for the more efficient replication of viral particles -- 3.3 Two modes of immune evasion: "Trojan Horse" (inner shell disorder) and "viral shapeshifting" (outer shell disorder) -- 3.4. FIV, HIV-1 and HIV-2: Similarities and differences -- 3.5. FIV vaccine enigma: Questionable efficacy -- 4. Conclusions -- 4.1. Development of the SARS-CoV-2 vaccine is feasible and vaccine strains can be found in nature -- 5. Materials and Methods -- References -- Protein Sequence Models for Prediction and Comparative Analysis of the SARS-CoV-2−Human Interactome -- 1. Introduction -- 2. Methods -- 2.1. Generalized Additive Models with interactions (GA2M) -- 3. Gold Standard Interaction Datasets -- 3.1. Dealing with the lack of negative examples -- 3.2. Features -- 4. Experiments -- 4.1. TAPE: Transformer based model for protein sequences -- 5. Results -- 5.1. Prediction performance and validation of predicted interactions -- 5.2. Enrichment analysis of predicted human binding partners -- 6. Discussion -- 6.1. Visualizing the virus-human interactions -- 6.2. Highly ranked sequence features -- 6.3. Structural analysis -- 7. Prior Work -- 8. Conclusion.

3.3. Age distribution by delivery admit type -- 3.4. Number of deliveries by weekday and admit type -- 4. Generalized regression model -- 4.1. Surgical Incision Type for C-section and Effect on Emergency Admission -- 5. Discussion -- References -- Co-occurrence Patterns of Intimate Partner Violence -- 1. Introduction -- 2. Materials and Methods -- 2.1. Description of Data and Pre-Processing -- 2.2. Co-Occurrence of Violence Types -- 2.3. Co-Occurrence Network of Individual Violence Items -- 2.4. Radial Visualization -- 2.5. Clustering of Survivors and Identification of Subgroups -- 2.6. Health Problems and Trauma Symptoms -- 3. Results -- 4. Discussion -- 5. Acknowledgments -- References -- BIOCOMPUTING AND AI FOR INFECTIOUS DISEASE MODELLING AND THERAPEUTICS -- Session Introduction: AI for Infectious Disease Modelling and Therapeutics -- 1. Background -- 2. Introduction -- 3. Social Media and COVID-19 -- 4. Biomedical literature and COVID-19 plus neglected tropical diseases -- 5. Genomics and HCV -- 6. Protein intrinsically disordered regions and SARS-CoV-2 -- 7. Protein-protein interactions and SARS-CoV-2 -- References -- Characterization of Anonymous Physician Perspectives on COVID-19 Using Social Media Data -- 1. Introduction -- 2. Methods -- 2.1. Data Collection -- 2.2. N-gram Frequency Measures -- 2.3. Sentiment Analysis -- 3. Results -- 3.1. Frequency of terms and n-grams -- 3.2. Sentiment analysis -- 3.3. Sentiments of tweets containing specific terms -- 4. Discussion and Conclusion -- 5. Acknowledgments -- References -- Semantic Changepoint Detection for Finding Potentially Novel Research Publications -- 1. Introduction -- 2. Methods -- 2.1. Data collection and general procedures -- 2.2. Title and abstract entropies -- 2.3. Bayesian changepoint analysis -- 2.4. Differential word clouds -- 2.5. Title and abstract embeddings.

001896319

express

(Au-PeEL)EBL6768316

(MiAaPQ)EBC6768316

(OCoLC)1236946435